Cue Biopharma (NASDAQ:CUE) VP Michael Vincent Meluzio Sells 5,628 Shares

Cue Biopharma, Inc. (NASDAQ:CUE) VP Michael Vincent Meluzio sold 5,628 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $30.09, for a total value of $169,346.52. Following the completion of the transaction, the vice president owned 48,961 shares in the company, valued at $1,473,236.49. This represents a 10.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cue Biopharma Stock Down 19.2%

Shares of NASDAQ:CUE opened at $27.64 on Tuesday. The business’s 50 day moving average is $29.47 and its 200 day moving average is $143.72. Cue Biopharma, Inc. has a 12-month low of $4.97 and a 12-month high of $45.50. The stock has a market cap of $116.09 million, a price-to-earnings ratio of -1.02 and a beta of 2.47.

Cue Biopharma (NASDAQ:CUE) last issued its quarterly earnings data on Friday, August 14th. The company reported ($24.14) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The company had revenue of $7.88 million for the quarter, compared to the consensus estimate of $3.00 million. Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 482.58%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. raised its stake in shares of Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after purchasing an additional 73,000 shares during the period. Squarepoint Ops LLC bought a new position in Cue Biopharma in the 3rd quarter worth approximately $62,000. Stifel Financial Corp lifted its position in shares of Cue Biopharma by 25.4% during the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after acquiring an additional 50,000 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc raised its stake in shares of Cue Biopharma by 1,231.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after purchasing an additional 407,568 shares during the period. Finally, Boothbay Fund Management LLC increased its position in shares of Cue Biopharma by 15.3% during the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock valued at $215,000 after buying an additional 93,333 shares during the period. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Cue Biopharma in a research report on Thursday. Wall Street Zen downgraded shares of Cue Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Cue Biopharma has a consensus rating of “Sell”.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.